Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

(2022) Nicole Wolter et al.   LANCET

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design

(2022) Aziz Sheikh et al.   LANCET INFECTIOUS DISEASES

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

(2022) Roanne Keeton et al.   NATURE

Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

(2021) Anthony T. Tan et al.   Cell Reports

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions

(2021) Opeyemi S. Adeniji et al.   mBio

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

(2021) Irfan Ullah et al.   IMMUNITY

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

(2021) Conrad E. Z. Chan et al.   PLoS One

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

(2021) Kathryn M. Hastie et al.   SCIENCE

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution

(2021) Jiří Zahradník et al.   Nature Microbiology

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

(2021) Shirley Collie et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct conformational states of SARS-CoV-2 spike protein

(2020) Yongfei Cai et al.   SCIENCE

Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial

(2020) Ricardo Palacios et al.   Trials

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

(2020) Tomer Zohar et al.   CELL

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

(2018) Bronwyn M. Gunn et al.   Cell Host & Microbe

Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design

(2017) Sinthujan Jegaskanda et al.   Human Vaccines & Immunotherapeutics

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

(2016) David J. DiLillo et al.   JOURNAL OF CLINICAL INVESTIGATION

Mouse and human FcR effector functions

(2015) Pierre Bruhns et al.   IMMUNOLOGICAL REVIEWS

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

(2011) L. Zeitlin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccines: Correlates of Vaccine‐Induced Immunity

(2008) Stanley A. Plotkin   CLINICAL INFECTIOUS DISEASES